Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.51 |
| ▸ | STS | P08842 | 2/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.48 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.45 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL226123 | 0.86 | KMO (0.55) | NAMPTMAPTKDM4ETHRBGPR119 | |
| SCHEMBL29769962 | 0.86 | KMO (0.55) | NAMPTMAPTKDM4ETHRBGPR119 | |
| SCHEMBL1558412 | 0.86 | NAMPT (0.54) | NAMPTMAPTKDM4ETHRBGPR119 | |
| SCHEMBL30563607 | 0.86 | GPR119 (0.65) | NAMPTMAPTKDM4ETHRBGPR119 | |
| SCHEMBL30673157 | 0.86 | NAMPT (0.54) | NAMPTMAPTKDM4ETHRBGPR119 | |
| SCHEMBL30376009 | 0.85 | GPR119 (0.54) | NAMPTMAPTKDM4ETHRBGPR119 | |
| SCHEMBL1427529 | 0.85 | NAMPT (0.53) | NAMPTMAPTKDM4ETHRBGPR119 | |
| SCHEMBL21523778 | 0.85 | TP53 (0.56) | NAMPTMAPTKDM4ETHRBGPR119 | |
| SCHEMBL30014833 | 0.85 | NAMPT (0.53) | NAMPTMAPTKDM4ETHRBGPR119 | |
| SCHEMBL835855 | 0.85 | GPR119 (0.54) | NAMPTMAPTKDM4ETHRBGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9108937-B2 | Positive allosteric modulators of mGluR2 | MERCK SHARP & DOHME CORP. (US) | 2015-08-18 | — | — | US | disclosed |
| US-20130158002-A1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | MERCK SHARP & DOHME LLC | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158002-A1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | GRM2, GRM1, GRM3 | NAMPT 3476/4885MAPT 976/4885KDM4E 1774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.